Filing Flows › ImmunityBio (IBRX) › Q3 2026 › vs Q3 2025
ImmunityBio (IBRX) Q3 2026 vs Q3 2025 (year over year)
ImmunityBio's revenue rose $16.8M (+52%) from $32.1M in Q3 2025 to $48.8M in Q3 2026.
ImmunityBio, Q3 2026: revenue $48.8M (+52% year over year), operating margin -159.7%, net loss $185M, operating cash flow −$75.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $48.8M | $32.1M | $16.8M | +52% |
| Net loss | $185M | $67.3M | $117M | +174% |
| Costs & expenses | $233M | $99.4M | $134M | +135% |
| Operating costs | $127M | $87.7M | $39.1M | +45% |
| Interest & other, net | $107M | $11.7M | $94.9M | +813% |
| Cost of revenue | $1.3M | $177K | $1.1M | +629% |
| Other operating costs | $126M | $87.5M | $38.0M | +43% |
| Operating cash sources | $185M | $67.3M | $117M | +174% |
| Depreciation & amortization | $3.9M | $4.0M | −$62K | -2% |
| Share-based compensation | $8.7M | $8.9M | −$162K | -2% |
| Working capital & other | $96.6M | −$14.5M | $111M | — |
| Cash used in operations | $75.3M | $68.9M | $6.4M | +9% |
| Net loss absorbed | $185M | $67.3M | $117M | +174% |
Questions
How much did ImmunityBio's revenue grow year over year in Q3 2026?
ImmunityBio's revenue rose $16.8M (+52%) from $32.1M in Q3 2025 to $48.8M in Q3 2026.